Unlike earlier GLP-1 receptor agonists, retatrutide is a triple agonist : GLP-1 receptor agonist suppresses appetite, slows gastric emptying, improves insulin sensitivity GIP receptor agonist enhances insulin release, amplifies GLP-1 effects Glucagon receptor agonist stimulates energy expenditure, fat metabolism, and potentially impacts lipid handling Clinical trials so far have shown remarkable weight loss (up to 24% in some studies) and strong metabolic improvements, including effects on lipids like LDL cholesterol
This commitment underscores our promise of personalized, medically supervised care, making sustainable weight loss attainable and tailored to you
Your digestive system acts like a strict filter - when you swallow vitamins, only about 10-50% survive the journey to reach your bloodstream
The revolution is underway, and with careful stewardship and continued research, GLP-1based strategies are poised to become an integral part of comprehensive, modern obesity care.